Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined further progress in its Skinject program following the release of Phase 2 topline data, alongside independent validation from a leading dermatology expert. The company's CEO Raza Bokhari said Medicus Pharma is advancing a novel, noninvasive treatment using patent-protected microneedle arrays designed to treat non-melanoma skin diseases, particularly basal cell carcinoma.